Outlook Therapeutics, Inc. (OTLK) financial statements (2021 and earlier)

Company profile

Business Address 4260 U.S. ROUTE 1
MONMOUTH JUNCTION, NJ 08852
State of Incorp. DE
Fiscal Year End September 30
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
TTM
9/30/2020
9/30/2019
9/30/2018
9/30/2017
9/30/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments6138232
Cash and cash equivalents6138232
Prepaid expense    02
Assets held-for-sale, not part of disposal group  1   
Other undisclosed current assets555211
Total current assets:111814346
Noncurrent Assets
Operating lease, right-of-use asset00 
Property, plant and equipment003181617
Restricted cash and investments     0
Other noncurrent assets110011
Total noncurrent assets:124191718
TOTAL ASSETS:132017222124
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities12129122113
Accounts payable3224115
Accrued liabilities685676
Taxes payable222222
Debt001101
Due to related parties 4    
Deferred revenue and credits31
Other undisclosed current liabilities00112056
Total current liabilities:121620322920
Noncurrent Liabilities
Long-term debt and lease obligation1110403
Long-term debt, excluding current maturities1110002
Finance lease, liability00 
Capital lease obligations300
Liabilities, other than long-term debt  4476
Deferred revenue and credits45
Other liabilities  4431
Other undisclosed noncurrent liabilities004416 
Total noncurrent liabilities:111811238
Total liabilities:231728435129
Temporary equity, carrying amount  553 
Stockholders' equity
Stockholders' equity attributable to parent(10)3(16)(26)(34)(5)
Common stock110100
Additional paid in capital292291238190152142
Accumulated deficit(304)(290)(254)(216)(186)(147)
Total stockholders' equity:(10)3(16)(26)(34)(5)
TOTAL LIABILITIES AND EQUITY:132017222124

Income statement (P&L) ($ in millions)

12/31/2020
TTM
9/30/2020
9/30/2019
9/30/2018
9/30/2017
9/30/2016
Gross profit:  8343
Operating expenses(43)(37)(44)(33)(40)(55)
Operating loss:(43)(37)(36)(30)(36)(52)
Interest and debt expense5(4)(4)(5)(6)(1)
Loss from continuing operations before equity method investments, income taxes:(38)(40)(40)(35)(42)(53)
Other undisclosed income (loss) from continuing operations before income taxes(0)2213 
Loss from continuing operations before income taxes:(38)(39)(38)(34)(38)(53)
Income tax expense (benefit)3334(1)(0)
Net loss:(35)(35)(35)(30)(39)(53)
Other undisclosed net income attributable to parent2     
Net loss attributable to parent:(33)(35)(35)(30)(39)(53)
Preferred stock dividends and other adjustments (0)(1)(2) (2)
Other undisclosed net loss available to common stockholders, basic(12)(13)(1)(16)(1)(7)
Net loss available to common stockholders, diluted:(45)(49)(36)(48)(40)(63)

Comprehensive Income ($ in millions)

12/31/2020
TTM
9/30/2020
9/30/2019
9/30/2018
9/30/2017
9/30/2016
Net loss:(35)(35)(35)(30)(39)(53)
Comprehensive loss, net of tax, attributable to parent:(35)(35)(35)(30)(39)(53)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: